We demonstrated that autoimmune encephalitis patients with low serum albumin (<4.0 g/dL) exhibited poor initial response to immune therapies at the third and fourth weeks after IVIg treatment compared to the high albumin patients. The gene discussed is ALB; the disease is autoimmune encephalitis.